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Cell-penetrating peptide mediated uptake of labels appears to follow an equilibrium-like process. However, this assumption is only valid if the
peptides are stabile. Hence, in this study we investigate intracellular and extracellular peptide degradation kinetics of two fluorescein labeled cell-
penetrating peptides, namely MAP and penetratin, in Chinese hamster ovarian cells. The degradation and uptake kinetics were assessed by RP-
HPLC equipped with a fluorescence detector. We show that MAP and penetratin are rapidly degraded both extracellularly and intracellularly
giving rise to several degradation products. Kinetics indicates that intracellularly, the peptides exist in (at least) two distinct pools: one that is
immediately degraded and one that is stabile. Moreover, the degradation could be decreased by treating the peptides with BSA and phenanthroline
and the uptake was significantly reduced by cytochalasin B, chloroquine and energy depletion. The results indicate that the extracellular
degradation determines the intracellular peptide concentration in this system and therefore the stability of cell-penetrating peptides needs to be
evaluated.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cell-penetrating peptide; Protein transduction domains; Uptake; Degradation; Endocytosis inhibitor1. Introduction
Cell-penetrating peptides (CPPs) or protein transduction
domains (PTDs) are peptides that translocate across the plasma
membrane of mammalian cells both in vitro [1,2] and in vivo
[3,4]. CPPs are capable of delivering functional cargos into cells,
such as oligonucleotides [5], peptide nucleic acids [6], plasmids
[7] and liposomes [8]. The mechanism by which CPPs enter cells
is not clear although many recent papers have indicated different
forms of endocytosis.
A few studies have investigated the metabolic stability or the
pattern of degradation of these peptides. In a paper by Elmquist
and colleagues the enzymatic degradation of pVEC and its all-DAbbreviations: CPP, cell-penetrating peptide; PTD, protein transduction
domain; fl-HPLC, fluorescence-HPLC; MAP, model amphipathic peptide; PBS,
phosphate buffered saline; IC, intracellular; EC, extracellular; CHO, Chinese
hamster ovarian
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doi:10.1016/j.bbamem.2007.03.029analog was investigated in buffer containing physiological
concentration of trypsin or carboxypeptidase A and B and the
half-lives were found to be 10.5 and 44.6 min in respective buffer
sample [9]. This was followed by another paper by Lindgren and
colleagues who investigated transportan, TP10 and penetratin in
contact with Caco-2 cells and found the stability of the peptides
was in the order of transportanNTP10Npenetratin [10]. More-
over, Tréhin and colleagues investigated Tat, penetratin and
several calcitonin analogs inMDCK, Calu-3 and TR146 cells and
found that the levels of proteolytic activity varied highly among
the cell lines tested [11].
Recently, we showed that the main mechanism by which
CPPs, or rather the cargo attached to the CPPs, accumulate in the
cellular interior is by the proteolytic processing of the CPP-cargo
conjugate into membrane impermeable products [12]. Hence, it is
of interest to characterize the degradation kinetics and products of
CPPs in order to investigate how they relate to cargo-delivery
efficiency. The understanding of the internalization and degrada-
tion kinetics of CPPs is important for the practical aspects of cargo
delivery. In uptake experiments, with incubation time points up to
1 h or longer, the peptide needs to be stabile outside themembrane
Table 1
Names and sequences of the cell-penetrating peptides used in this work
Peptide Sequence
MAP(KLAL)
[16]
Fluo-KLALKLALKALKAALKLA-amide
Penetratin
[19]
Fluo-RQIKIWFQNRRMKWKK-amide
Perforin
1–16 [15]
Fluo-PCHTAARSECKRSHKF-amide
Perforin
1–34 [15]
Fluo-
PCHTAARSECKRSHKFVPGAWLAGEGVDVTSLRR-amide
1770 C. Palm et al. / Biochimica et Biophysica Acta 1768 (2007) 1769–1776and not degraded within that time, hence, evaluation of peptide
stability is an important parameter. These studies are also essential
in order to achieve a better understanding of the mechanism by
which CPPs pass through membranes and enter cells.
In this study we investigate intracellular (IC) and extracellular
(EC) peptide degradation products and kinetics of two structurally
different CPPs, namely MAP and penetratin. The degradation
products and kinetics of fluorescently labeled MAP and penetratin
after incubation with Chinese hamster ovarian (CHO) cells were
assessed by RP-HPLC equipped with a fluorescence detector. Data
obtained from the experimentswere used to generate a schematic of
different pathways in uptake of the peptides. An attempt to inhibit
degradation of the peptides was made by using several common
protease inhibitors and the toxicity of these protease inhibitors and
substrates was investigated in an LDH leakage assay. Wortmannin,
cytochalasin B and nocodazole, which have previously been shown
to inhibit different forms of endocytosis [13], were analyzed for
their effect on uptake of MAP and penetratin. In addition, the
uptake and degradation was investigated in cells treated with
chloroquine and in energy depleted cells.
2. Materials and methods
2.1. Materials
5(6)-Carboxyfluorescein was purchased from Molecular Probes. All amino
acids were purchased from Bachem, Switzerland. Cell culture medium DMEM-
F12, Foetal Bovine Serum (FBS), Bovine Serum Albumin (BSA), Penicillin–
Streptomycin (PEST) and Trypsin were purchased from GIBCO, USA. Other
chemicals and reagents, when not specified were purchased from Sigma-Aldrich.
Data evaluation was performed using the software GraphPad Prism 4.0 from
GraphPad soft Inc.
2.2. Peptide synthesis
Peptides (Table 1) were synthesized in a stepwisemanner in a 0.1mmol scale on
a peptide synthesizer (Applied Biosystems model 431A, USA) using t-Boc strategy
of solid-phase peptide synthesis. t-Boc amino acids were coupled as hydroxybenzo-
triazole (HOBt) esters to a p-methylbenzylhydrylamine (MBHA) resin to
obtain C-terminally amidated peptides. The peptides were labeled with 5-(and-6)-
carboxyfluorescein asHOBt ester at theN-terminus as described in Fischer et al. [14].
The peptides were finally cleaved from the solid phase with liquid HF at 0 °C for 1 h
in the presence of p-cresol (and thiocresol 1:1 for penetratin). Purification of peptides
with reverse-phase (RP) HPLC was carried out with a Supelcosil LC-18 preparative
column 5 μm (250×21.2 mm) (Sigma Aldrich Chemie, Steinheim, Germany) using
acetonitrile–water, both containing 0.1% trifluoroacetic acid, gradient from 20 to
100% acetonitrile. Correct masses of purified peptides were obtained using a Perkin
Elmer prOTOF™ 2000 MALDI O-TOF mass spectrometer.2.3. Cell culture
CHO-K1 cells were cultured in Dulbecco's Modified Eagle's Media
(DMEM) F-12 with Glutamax-I (GIBCO, USA) supplemented with 10% foetal
calf serum, 100 μg/ml streptomycin, 100 U/ml penicillin.
2.4. Cellular uptake experiments
CHO cells seeded in 24-well plates in 500 μl medium (200,000 cells/well)
were used for experiments performed in triplicates 1 day after seeding. Cells for
uptake experiments were washed 2 times with ice-cold PBS and incubated with
200 μl, 1 μMpenetratin orMAP in PBS buffer supplemented with 1g/l D-glucose
at 37 °C for 5, 15, 30 or 60 min. As negative controls we used two sequences
originating from the pore forming perforin protein, namely, amino acids 1–16
and 1–34 [15]. After each time point, the incubation buffer containing the
peptides was removed, diluted with 0.1% Triton X-100 containing 0.1%
trifluoroacetic acid and injected to HPLCwhere quantification was performed by
fluorescence measurement at 524 nm after excitation at 445 nm using calibration
values obtained with 10 pmol of the parent peptide analyzed under identical
conditions. The cells were washed 2 times with ice-cold PBS, incubated with
500 μl of ice-cold PBS and treated with diazotized 2-nitroaniline as described
previously [16] in order to modify any remaining extracellularly located peptide.
Briefly: to 400 μl ethanol/water 1/1 v/v containing 2-nitroaniline (0.06 M) and
HCl (0.125 M), 50 μl 0.6 M NaNO2, were added. After standing for 5 min at
ambient temperature, 10 μl of this reagent was added to the ice-cold PBS
covering the cell layer and allowed to react for 10 min at 0 °C. After aspiration of
the diazo reagent the cells were washed 2 times with ice-cold PBS and finally
lysed with 200 μl 0.1% Triton X-100 containing 0.1% trifluoroacetic acid for 2 h
at 0 °C. The resulting lysates were used for HPLC-analysis. The effects of the
protease inhibitors, bacitracin (5 mg/ml), leupeptin (50 μM), phenanthroline
(2 mM), PMSF (2 mM) were analyzed by incubating cells with MAP or
penetratin together with each inhibitor or BSA (1%) at 37 °C for 1 h. In addition
BSA and bacitracin were pre-incubated with the peptides 40 min prior to
incubation with cells. In order to investigate the endocytosis inhibitors, the cells
were pre-incubated with wortmannin (5 nM), nocodazole (5 μM) or cytochalasin
B (5 μM) for 30 min, followed by incubation with peptides in the presence of
inhibitors for 1 h at 37 °C. The same procedure was performed with chloroquine
(50 μM) and sodium azide (60 mM) together with deoxyglucose (20 mM).
Samples were taken and analyzed by RP-HPLC.
2.5. LDH leakage assay
The assay was performed using the In Vitro Toxicology Assay Kit, Lactic
Dehydrogenase Based (Sigma). In the assay, CHO cells were seeded in 24-well
plates in 500 μl medium (100,000 cells/well) and used for experiments
performed in triplicates 1 day after seeding. Prior to the incubation with 100 μl
peptide and 100 μl inhibitor at 37 °C, cells were washed with PBS buffer
supplemented with 1 g/l D-glucose two times. After 1 h incubation, samples of
100 μl were added to 200 μl of an equal mixture of LDH Assay Substrate,
Cofactor and Dye solution in a 96-well-plate and incubated at 21 °C. After
30 min the reaction was quenched with 1/10 of 1M HCl. The absorbance was
measured at 490 nm and the background absorbance was measured at 690 nm
and subtracted. Untreated cells and cells treated with LDHAssay Lysis Solution,
were used as controls.
2.6. HPLC-analysis
HPLC was performed using a Gynkotek-HPLC-gradient system (Dionex,
USA) equipped with a 5 μm (150×4.6 mm, ) C18 column, a precolumn
containing the same adsorbent and a fluorescence detector. The elution was
carried out with water containing 0.1% TFA (A) and acetonitrile containing
0.1% TFA (B) at a flow rate of 1.0 ml/min with gradients from 100% A (5 min)
20% B (5–10 min) and 20–100% B (10–50 min). Quantification was performed
by fluorescence measurement at 524 nm after excitation at 445 nm using
calibration values obtained with 10 pmol of the parent peptide analyzed under
identical conditions.
Fig. 1. EC degradation of MAP (□) and penetratin (◼). The graph illustrates
how intact MAP and penetratin decreases over time after cells were incubated
with 1 μMof each peptide at different time points. Each time point represents the
mean of three independent experiments±S.E.M.
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EC degradation was fitted to Eq. (1) (A→D) and the resulting constant was
used in fitting the kinetic data to Eq. (2) (A→D A→Z, Z→B) where A
corresponds to intact EC peptide which can be degraded to D, extracellularly. Z is
peptide bound to the membrane and B is total IC label. Finally, the constants
obtained from Eq. (1) and Eq. (2) was used to fit the data to Eq. (3): (A→DA→Z,
Z→B, Z→C, B→C) where A corresponds to intact EC peptide which can be
degraded to D, extracellularly. Z is peptide bound to the membrane internalized to
either intact IC peptide, B or degraded IC peptide, C. In addition, intact IC peptide
B can be degraded to C, intracellularly. For the fitting, the Gepasi 3.0 program
package with the evolutionary programming method run for 500 generations, for
global optimisation followed by Hook and Jeeves local optimisation was used
[17,18]. Fitting constrains were set to 0bconstantsb100 and the IC volume to
0.5 μl. The membrane volume was set to 1% of cell volume.Fig. 2. Uptake and IC degradation of MAP (A) and penetratin (B). The curves
correspond to IC intact (▪) and degraded (▴) peptide after incubation with
1 μM of each peptide at different time points. Each time point represents the
mean of three independent experiments±S.E.M.3. Results
In this study detailed fluorescence-HPLC (fl-HPLC) exami-
nation was used to obtain quantitative data on uptake and
degradation of CPPs. In all studies relating to peptide uptake it is
critically important to separate membrane attached peptide from
internalized peptide. To achieve this, cells were treated prior to
cell lysis with diazotized 2-nitroaniline, which is a chemical agent
that binds to primary amino groups [16]. After the modification
the peptide will be more hydrophobic and have a longer retention
time in the HPLC. Internalized and membrane bound peptides are
separated since the reagent cannot cross the plasma membrane
and modify internalized peptides.
The uptake and degradation time-course of fluorescently
labeled MAP and penetratin was investigated in CHO cells using
fl-HPLC. The cells were incubated with various concentrations of
peptide at 37 °C at different time points. The curves in Fig. 1
illustrate the EC degradation of MAP and penetratin at 1 μM.
Half-lives of EC degradation were calculated with first-order
kinetics and corresponded to about 5 min (k = 0.0024) and 10min
(k = 0.0012) for penetratin and MAP, respectively. The disap-
pearance of the intact peptide peak coincided with an increase in
peaks corresponding to peptide fragments. In order to ascertain
that indeed the disappearance of the intact peptide peakwas due to
degradation, not precipitation or plastic binding, parallel treat-
ments in cell-free conditions were applied. Here no change inpeptide levels after 1 h was seen (data not shown). This also rules
out that residual trypsin from the cell-culturing process were
responsible for the degradation. Peptide stability in buffer condi-
tioned for 1 h on cells was analyzed, and again no degradation
could be seen after 1 h incubation at 37 °C.
The uptake ofMAP and penetratin is illustrated in Fig. 2 where
the IC degradation for both peptides is similar, whereas the curves
corresponding to intact peptide differ. Studying the curve
corresponding to MAP (Fig. 2A), intact peptide increases for
1 h whereas intact penetratin (Fig. 2B) starts to decrease after
15 min, which correlate well with the half-lives of the peptides.
After 15 min almost all EC penetratin should be degraded, hence;
IC intact peptide should decrease whereas MAP, which has a
longer half-life, continues to have an increase in IC intact peptide.
When comparing the uptake of MAP (Fig. 3A) and penetratin
(Fig. 3B) to the formation of EC degradation products, both
curves correlate quite well and indicate that EC degradation, not
equilibrium, could be determining the IC concentration. In
accordance with earlier studies [12], the main IC degradation
product, regardless of peptide, corresponded to the fluorescently
labeled N-terminal amino acid (data not shown). Moreover,
several shorter peptides could be identified extracellularly.
However, the EC degradation products could not be found
intracellularly nor could the IC degradation products be found
extracellularly.
Fig. 4. Effects of protease inhibitors and BSA on EC peptide degradation (A)
and uptake (B). The protease inhibitors, bacitracin (5 mg/ml), leupeptin
(100 μM), phenanthroline (2 mM), PMSF (2 mM) or BSA (1%) were incubated
with MAP (white) or penetratin (black) for 1 h at 37 °C followed by analysis
with fl-HPLC. The data represent the mean of three independent experiments±
S.E.M. Statistical analysis was made by ANOVA followed by Dunnett's
multiple comparison test (*P b 0.05, **P b 0.01).
Fig. 3. A comparison between total uptake and EC degradation of MAP (A) and
penetratin (B). The curves correspond to the formation of EC degradation
products (◼) and the total uptake, intact and degraded, IC peptide concentration
(▴). For ease of comparison both data sets are shown as fraction of maximum,
where the maximum corresponds to 0.91 ± 0.09 μM and 0.84 ± 0.11 μM for
MAP and penetratin, respectively. Each time point represents the mean of three
independent experiments ± S.E.M.
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protease inhibitors covering the most common proteases namely,
leupeptin, which is an inhibitor of serine and cysteine proteases,
phenanthroline, which inhibits matrix metalloproteases (MMPs),
phenylmethylsulfonyl fluoride (PMSF), an inhibitor of serine
proteases and bacitracin, a non-specific protease inhibitor. In
addition, BSA was analyzed in order to investigate if it could
saturate proteases resulting in an increase in intact EC peptide. Cells
were incubated with inhibitors or BSA at different concentrations
together withMAP or penetratin (Fig. 4) for 1 h at 37 °C. Leupeptin
and PMSF did not increase the intact EC peptide significantly and
the IC and EC peptide concentration of bacitracin could not be
determined properly due to a new broad peak found in the
background of the bacitracin treated samples (Fig. 4A). To
determine the origin of the peak, bacitracin was analyzed alone,
together with diazotized 2-nitroaniline or peptides. The results
indicated that bacitracin alone could cause this broad peak but that it
was even stronger together with peptides (data not shown).
Treatment with 1% BSA increased the EC intact MAP with more
than 50%, whereas, penetratin was unaffected by the BSA
treatment. Unfortunately, the increment of EC intact MAP due to
BSA treatment did not affect the uptake (Fig. 4B). To investigate if
this was due to complex formation between the peptides and BSAwe incubated each peptide with BSA or bacitracin prior to
incubationwith cells. The pre-incubation led in both cases to a 50%
decrease of MAP whereas penetratin was unaffected. Phenanthro-
line increased EC intact MAP and penetratin by more than 2-fold
(Fig. 4A) and the degradation products disappeared in both EC and
IC samples (data not shown). Here, the uptake of penetratin was
increased almost 2-fold whereas the uptake ofMAP decreased with
both phenanthroline and PMSF (Fig. 4B). To investigate if the
protease inhibitors affected the uptake or degradation due to
toxicity, cells were incubated with peptides and/or inhibitors, and
subjected to a LDH leakage test (Fig. 5). No toxicity was found for
the peptides alone or with leupeptin. However, MAP together with
PMSF and phenanthroline caused 25% of maximal leakage.
Fig. 5. Cytotoxicity of different protease inhibitors and peptides. Cells were
incubated for 1 h at 37 °C with phenanthroline (2 mM), PMSF (2 mM) or
leupeptin (100 μM) together with MAP (white) or penetratin (black) followed by
an LDH leakage test. Leakage is shown as percent of maximum. The data
represent the mean of at least three independent experiments±S.E.M.
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10% with phenanthroline.
Moreover, three inhibitors of endocytosis were studied for their
effect on uptake namely, nocodazole, which blocks IC transport by
depolymerizing microtubules, cytochalasin B which inhibits the
assembly of actin filaments and thereby blocks IC transport and
wortmannin, a phosphoinositide 3-kinase inhibitor which inhibits
the fusion of early endosomes with late endosomes (Fig. 6). In
addition, the uptake was investigated in energy depleted cells and
cells treated with chloroquine, an inhibitor of maturation and
formation of transport vesicles into late endosomes. Cytochalasin
B reduced the uptake of both peptides with almost 30% and
chloroquine inhibited the uptake with more than 50 and 40% for
MAP and penetratin, respectively. In energy depleted cells the
uptake ofMAPwas reduced more than 60%.Wortmannin, energy
depletion and nocodazole decreased the uptake of penetratin with
25%, however, it could not be statistically ascertained.
Finally, the data were analyzed using Gepasi 3.0, a program
used for modeling the kinetics of biochemical systems and
pathways [17,18]. The data were fitted to the equations seen in Fig.
7whereA corresponds to intact EC peptidewhich can be degraded
to D, extracellularly. Z is peptide bound to the membrane
internalized to either intact IC peptide B, or degraded IC peptideC.
In addition, intact IC peptide B can be degraded to C,
intracellularly. In summary, the fitting indicated two uptake
processes; one resulting in degraded peptides (Z→C) possibly
through direct delivery to the cytoplasm, where it can be degraded
within minutes, and another process delivering intact peptides
(Z→B), possibly by endosomal encapsulation, shielding the
peptides from proteases in the cytoplasm. The degradation of
B→C could illustrate the escape of peptides from endosomes. The
half-lives of the uptake and degradation processes, derived from
Gepasi, are displayed in Table 2 and correlate well with the uptake
and degradation of MAP and penetratin in Figs. 1 and 2.
4. Discussion
The translocation of CPPs into cells was first thought to be
independent of metabolic energy [19,20]. Today, several well-
characterized CPPs have been shown to enter cells by different
types of endocytosis [13,21,22]. However, none of the endocytosis
inhibitors could inhibit the uptake totally. Nevertheless, the
capacity of CPPs to deliver cargo molecules to the cell interior,
as shown by the presence ofmany different biological responses of
treated cells, proves that the cargo is successfully delivered in a
functional state [23] and has opened up new possibilities in drug
delivery research [24,25]. A crucial aspect of drug delivery is, of
course, efficient transport of the pharmaceuticals to the site of
action, but also the following clearance of the transporting moiety
from the cell. The CPP needs to translocate its cargo before it is
extracellularly degraded, although, well inside the cell it has to be
eliminated in order not to cause toxicity. In addition, if the CPPs
remain intact in the cellular environment, there is a possibility that
the peptide-cargo conjugate could leak back to the EC
environment. Hence, IC degradation of CPPs is important for
cargo delivery, and degradation kinetics is an important parameter
to include when choosing a peptide to act as a delivery vector.Kinetic measurements of CPP degradation are so far sparse.
Tréhin and colleagues followed the degradation of Tat,
penetratin and several calcitonin analogues in three different
epithelial cell lines [11]. This study concluded that the EC half-
life of the individual peptides depended on cell type and cell
density in the experiment. The shortest half-life measured was
50 min for penetratin exposed to Calu-3 cells. However, the
stability of the peptides varied widely, and the longest half-life
was 1444 min for Tat(48–60) exposed to MDCK cells. In
another paper by Rennert and colleagues, the proteolytic
resistance of hCT(9–32) was increased in human blood plasma
and HEK 293T cell culture supernatants, by replacing the amino
acids at position 12 and 16 with either N-methylphenylalanine
or D-phenylalanine [26]. However, these studies did not include
intracellular degradation and how it affects the uptake.
In this study MAP and penetratin were incubated with CHO
cells and the EC half-lives corresponded to 10 and 5min (Table 2),
respectively. In contrast, in conditioned buffer no degradation
could be seen after 1 h, indicating that the proteases responsible for
EC degradation are membrane bound rather than soluble. The EC
degradation of MAP but not penetratin could be reduced by the
addition of BSA (Fig. 4A), however, no corresponding increase in
IC peptide concentration could be seen (Fig. 4B). On the contrary,
pre-incubation of MAP with BSA or bacitracin reduced its uptake
whereas penetratin was unaffected. This increase in stability
without a corresponding increase in uptake probably is due to
complex formation between the peptides and BSA or bacitracin,
shielding them from proteases but preventing them from
translocating the cell. This is supported by the appearance of the
new broad peak in the HPLC spectrums (data not shown). The
structural differences between MAP and penetratin could explain
the different effects of BSA on EC degradation of MAP and
penetratin, indicating that BSA is able to bind and shield MAP
from proteases but not penetratin. Phenanthroline, which inhibits
MMPs, increased the EC stability of both MAP and penetratin,
with a corresponding increase in uptake for penetratin. However,
both phenanthroline andPMSFdecreased the uptake ofMAP. This
was probably due to toxicity, which was supported by the LDH
Table 2
Half-lives of internalization and degradation for MAP and penetratin
Half-lives Penetratin (min) MAP (min)
A→D(1) 5.7 10
A→Z(2) 123 110
Z→B(3) 2.3 6.2
Z→C(4) 4.2 2.7
B→C(5) 20 86
Fig. 6. Effects of different inhibitors on uptake. Cells were preincubated for 30 min
with chloroquine (50 μM), wortmannin (5 nM), sodium azide (60 mM) and
deoxyglucose (20 mM), cytochalasin B (5 μM) or nocodazole (5 μM) followed by
incubationwithMAP (white) or penetratin (black) for 1 h at 37 °C. The data represent
the mean of three independent experiments±S.E.M. Statistical analysis was made by
ANOVA followed by Dunnett's multiple comparison test (*P b 0.05, ***P b 0.001).
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but not penetratin (Fig. 5).
Studying the IC concentrations, intact penetratin increased
rapidly the first 5 min whereas intact MAP continuously increased
after 15 min. This correlates with the uptake half-lives (Table 2)
where MAP had a 3 times longer half-life than penetratin (Fig. 2).
Moreover, IC intact penetratin started to decrease after 15minmost
likely due to the short EC half-life, indicating that the EC
degradation could be determining the IC concentration, which is
corroborated by the comparison of uptake and formation of EC
degradation products (Fig. 3). Even though it may appear that the
peptides are in equilibrium over the plasma membrane, this is
unlikely since the IC degradation is rapid and does not result in the
same degradation products as the EC degradation.
In accordance with earlier studies [13,27], cytochalasin B
decreased the uptake of both peptides with approximately 30%
(Fig. 6) indicating that the uptake is partly dependent on theFig. 7. Schematic of the proposed mechanisms in uptake. The equations were
derived from analyzing the data with the Gepasi 3.0 program package, illustrating
EC intact peptide (A), EC degraded peptide (D), membrane bound peptide (Z), IC
intact peptide (B) and IC degraded peptide (C).assembly of actin filaments for IC transport and confirms that
some form of endocytosis is involved. Chloroquine, a membrane
disrupting agent that increases the lysosomal pH and prevents the
maturation and formation of transport vesicles into late
endosomes, decreased the uptake of both peptides with 40–
50%. Wortmannin and nocodazole did not have a significant
effect on the uptake at these concentrations; however, the uptake
of penetratin was decreased by 25% augmenting the involvement
of endocytosis. In addition, the uptake of MAP was found to be
energy dependent since the IC concentration of MAP decreased
with 60% in energy depleted cells. Surprisingly the uptake of
penetratin did not decrease in energy depleted cells significantly,
which was expected since the uptake of penetratin decreased with
cytochalasin B, which inhibits an energy dependent mechanism.
One explanation could be that the variation in uptake was not
statistically significant and what appeared to be a decrease in
uptake of penetratin could not be ascertained. These results
indicate that the uptake of MAP is partly energy dependent and
that endocytosis, requiring the assembly of actin filaments for
transport, is involved in the uptake of both peptides in this system.
It is important to note that the total label content in the cells
appear to reach an equilibrium (Fig. 3) [28–31]. In this work we
show that this is in fact determined not by the export/import rate
constants but mainly by the EC degradation/import rate constants.
This was corroborated by comparing the curve for total IC label
(intact and degraded) to the curve corresponding to the formation
of EC degradation products (Fig. 3). Both curves correlate well
indicating that EC degradation and not equilibrium, determines the
IC concentration. It is conceivable that peptide fragments could
pass the plasma membrane in both directions. We consider this as
less likely as the EC degradation products are not the same as the
IC degradation products (data not shown). In addition, it has
previously been shown that C-terminally truncated forms of both
MAP [32] and penetratin [33] are not translocated into cells, or
retained, as efficiently as the parent peptides. From this we can
presume that what appears to be transport equilibrium, in fact is not
and that saturation like effects are probably due to EC degradation.
This would explain the discrepancy reported by our group
previously [34]. However, it is possible that equilibrium can be
reached if the peptide stability would be substantially better.
Moreover, from transport kinetics we know that the concentra-
tion found in cells should be dependent on the ratio between inside
and outside volumes [35], which was experimentally verified for
CPPs by our group recently [12]. However, this is now complicated
by the fact that degradation is dependent on the cell amount, (and
hence protease concentration). Thus, at the same time as the IC
volume increases, leading to a decrease of IC concentration, also
the EC degradation rate will increase, further decreasing uptake.
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decreases (Fig. 2), we propose that there could be twomechanisms
involved in the uptake of CPPs. A representation of this hypothesis
is shown in Fig. 7 and the half-lives of the processes are shown in
Table 2. From our fitting we can see that the first mechanism,
resulting in IC degraded peptides (Z→C in Fig. 7), could be
translocation of the peptides directly to the cytoplasm where they
can be rapidly degraded. It has been shown previously that
peptides in the cytoplasm are degraded within seconds [36],
however, in this study the peptides were injected directly to the
cytoplasm and transport across the plasma membrane was not
taken into consideration. Alternatively, a rapid endocytosis
followed by an immediate escape from endosomes to the
cytoplasm could be responsible. The other uptake mechanism,
resulting in IC intact peptides (Z→B in Fig. 7), could be some
form of vesicle formation shielding the peptides from proteases in
the cytoplasm. This is supported by the fact that we could detect
intact peptides intracellularly after 1 h in spite of rapid IC
degradation. Another explanation could be that this stabile pool of
peptide is deposited in the nucleus or other proteolytically
privileged sites. Moreover, it should be noted that the half-life
for several processes are in the order of 2 times longer or shorter
than the longest or shortest time measured, which is slower or
faster than we can measure. From the fitting we conclude that
MAP predominantly uses the first mechanism, while penetratin
mostly uses the second, which is in accordance with Fig. 2. This
model is attractive as it would possibly include various forms of
endocytosis (Z→B), endosomal escape (B→C) and direct cell-
penetration (Z→C).
We have shown that MAP and penetratin are degraded
extracellularly with half-lives of 10 and 5 min, respectively, and
that decreasing EC degradation can increase the uptake. This is
important since at least penetratin is a popular peptide used in
many uptake studies where incubation time points sometimes are
several hours and even though MAP is not as common as
penetratin, there are amphiphilic peptideswith structures similar to
MAP. In conclusion, EC degradation is a critical determinant for
delivery efficiency as all peptide is degraded before transport is
saturated, thus, the stability of cell-penetrating peptides needs to be
evaluated.
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